Sunny Pharmtech Aims to Submit 7 Drug License Applications This Year, Backed by 4 Advantages for US-Japan Strategic Collaboration

On May 2, Sunny Pharmtech (6676.TWO) held an investor conference, during which chairman Dr. Yon-Lian Wu announced to expand their layout of drug license to markets outside the US this year. In terms of niche generic drugs, the company currently has 5 products selling on the US market, with 5 drugs undergoing the FDA's drug review process. Additionally, they are developing more than 10 products, aiming to submit 7 applications this year and hoping to obtain 3 licenses annually.
 
Moreover, Sunny Pharmtech will optimize its supply chain to ensure stable raw material supply, accelerate strategic alliances for resource integration, and actively seek international CDMO/CMO orders. The company is currently establishing strategic partnerships with pharmaceutical companies in countries including the UK, Switzerland, Greece, Japan, and the US.
 
Find more news and insights from GlobalBio's: https://lnkd.in/eH_2RPSK

#pharmaceutical #SunnyPharmtech #CDMO #drug